- Home
- LYEL
as 12-20-2024 3:39pm EST
Lyell Immunopharma Inc is a clinical-stage cell therapy company. It has a pipeline of product candidates for patients with solid tumors utilizing ex vivo genetic and epigenetic T-cell reprogramming technologies. The company's product pipeline includes, LYL797, LYL119, LYL845 among others.
| Founded: | 2018 | Country: | United States |
| Employees: | N/A | City: | SOUTH SAN FRANCISCO |
| Market Cap: | 263.9M | IPO Year: | 2021 |
| Target Price: | $1.00 | AVG Volume (30 days): | 1.5M |
| Analyst Decision: | Sell | Number of Analysts: | 2 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.80 | EPS Growth: | N/A |
| 52 Week Low/High: | $0.58 - $3.26 | Next Earning Date: | 11-07-2024 |
| Revenue: | $63,000 | Revenue Growth: | -99.87% |
| Revenue Growth (this year): | -82.74% | Revenue Growth (next year): | N/A |
Latest Lyell Immunopharma Inc. News
LYEL Breaking Stock News: Dive into LYEL Ticker-Specific Updates for Smart Investing
Zacks
9 days ago
Down -30.89% in 4 Weeks, Here's Why Lyell Immunopharma (LYEL) Looks Ripe for a Turnaround
GlobeNewswire
13 days ago
Lyell Presents Positive Initial Clinical Data from the Phase 1-2 Clinical Trial of IMPT-314 for the Treatment of B-cell Lymphoma at the 2024 ASH Annual Meeting
Zacks
a month ago
Lyell Immunopharma (LYEL) Upgraded to Buy: Here's What You Should Know
Associated Press Finance
a month ago
Lyell Immunopharma: Q3 Earnings Snapshot
GlobeNewswire
a month ago
Lyell Immunopharma Reports Business Highlights and Financial Results for the Third Quarter 2024
GlobeNewswire
2 months ago
Lyell Announces Presentation of Initial Clinical Data from the Phase 1-2 Clinical Trial of IMPT-314 for the treatment of B-cell Lymphoma at the 2024 American Society of Hematology (ASH) Annual Meeting
Simply Wall St.
2 months ago
LiveOne Leads The Pack Of 3 US Penny Stocks
GlobeNewswire
2 months ago
Lyell Immunopharma Completes Acquisition of ImmPACT Bio
Compare LYEL vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "LYEL Lyell Immunopharma Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.